Related Experiment Video
Updated: Apr 3, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Nanoparticle mediated chemotherapy of hormone refractory prostate cancer with a novel combi-molecule
You-Qiang Fang1, Jie-Ying Wu1, Teng-Cheng Li1
1Department of Urology, The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630, China.
Abstract:
In previous study, we synthesized a novel combi-molecule, JDF-12, with superior cytotoxicity against prostate cancer cells, but it has a poor stability in liquid after preparation with traditional method and is susceptible to hydrolysis and binding to organs highly expressing epidermal growth factor receptor (EGFR), resulting in side effects. In this study, the nanotechnology was employed to prepare JDF-12 aiming to increase its anti-tumor effect and reduce its systemic side effects. The JDF-12 loaded nanoparticles were formulated with biocompatible and biodegradable poly (D,L-lactic-co-glycolic acid)-block-poly(ethyleneglycol) (PLGA-b-PEG) copolymer and surface functionalized with a single-chain antibody that recognizes the extracellular domain of prostate stem cell antigen (PSCA), enabling a controlled release, "stealth" property, and cell-specific targeting. The targeted nanoparticles exhibited a sustained drug release in vitro and were specifically endocytosed by prostate cancer cells though the receptor-mediated endocytosis resulting in enhanced cellular toxicity in vitro. Moreover, a better outcome with reduced drug toxicity was observed in a PC3M xenograft animal model after treatment with these nanoparticles. Our results demonstrate the feasibility of nanoparticle-based technology in the development of pharmaceutically suboptimal chemotherapeutics.
Insights
Nanoparticles enhance the anti-cancer drug JDF-12's effectiveness against prostate cancer. This nanotechnology improves drug stability and targets cancer cells, reducing side effects for better treatment outcomes.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- The novel anti-prostate cancer drug JDF-12 exhibits high cytotoxicity but suffers from poor stability and off-target side effects.
- Traditional preparation methods lead to drug hydrolysis and binding to EGFR-expressing organs, limiting therapeutic potential.
Purpose of the Study:
- To enhance the anti-tumor efficacy of JDF-12 and mitigate its systemic side effects using nanotechnology.
- To develop targeted nanoparticles for improved prostate cancer treatment.
Main Methods:
- JDF-12 was encapsulated in poly(D,L-lactic-co-glycolic acid)-block-poly(ethyleneglycol) (PLGA-b-PEG) nanoparticles.
- Nanoparticles were surface-functionalized with a single-chain antibody targeting prostate stem cell antigen (PSCA).
- In vitro drug release, cellular uptake via receptor-mediated endocytosis, and cytotoxicity were evaluated. In vivo efficacy was assessed in a PC3M xenograft model.
Main Results:
- Targeted nanoparticles demonstrated sustained JDF-12 release in vitro.
- Prostate cancer cells specifically internalized the nanoparticles through receptor-mediated endocytosis, leading to enhanced cytotoxicity.
- In vivo studies showed improved therapeutic outcomes with reduced drug toxicity in a PC3M xenograft model.
Conclusions:
- Nanoparticle formulation significantly improves the pharmaceutical properties and therapeutic potential of JDF-12.
- This nanotechnology approach offers a viable strategy for developing suboptimal chemotherapeutics into effective anti-cancer agents.
- Targeted delivery via PSCA-functionalized nanoparticles enhances anti-tumor activity and reduces systemic side effects in prostate cancer treatment.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...